Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M140,253Revenue $M39,553Net Margin (%)13.3Altman Z-Score2.5
Enterprise Value $M151,687EPS $2.0Operating Margin %18.9Piotroski F-Score5
P/E(ttm)27.0Beneish M-Score-2.4Pre-tax Margin (%)17.5Higher ROA y-yY
Price/Book2.310-y EBITDA Growth Rate %2.7Quick Ratio0.9Cash flow > EarningsN
Price/Sales3.65-y EBITDA Growth Rate %-2.9Current Ratio1.4Lower Leverage y-yN
Price/Free Cash Flow53.1y-y EBITDA Growth Rate %8.7ROA % (ttm)8.5Higher Current Ratio y-yN
Dividend Yield %3.0PEG--ROE % (ttm)14.8Less Shares Outstanding y-yN
Payout Ratio %79.0Shares Outstanding M2,622ROIC % (ttm)14.3Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYKen Fisher 2015-06-30 Add0.02%$48.81 - $52.35
($50.66)
$ 53.496%Add 1.44%13,246,593
SNYNWQ Managers 2015-03-31 Add0.61%$44 - $51.12
($47.81)
$ 53.4912%Add 33.50%3,927,517
SNYJames Barrow 2015-03-31 Reduce-0.04%$44 - $51.12
($47.81)
$ 53.4912%Reduce 1.88%30,225,221
SNYHOTCHKIS & WILEY 2015-03-31 Add0.02%$44 - $51.12
($47.81)
$ 53.4912%Add 0.77%11,782,180
SNYThird Avenue Management 2015-03-31 Sold Out -0.012%$44 - $51.12
($47.81)
$ 53.4912%Sold Out0
SNYDodge & Cox 2015-03-31 Reduce-0.01%$44 - $51.12
($47.81)
$ 53.4912%Reduce 0.55%43,034,073
SNYFirst Eagle Investment 2015-03-31 Sold Out -0.0038%$44 - $51.12
($47.81)
$ 53.4912%Sold Out0
SNYKen Fisher 2015-03-31 Reduce$44 - $51.12
($47.81)
$ 53.4912%Reduce 0.21%13,058,095
SNYMario Gabelli 2015-03-31 Reduce$44 - $51.12
($47.81)
$ 53.4912%Reduce 9.53%4,700
SNYCharles Brandes 2015-03-31 Add$44 - $51.12
($47.81)
$ 53.4912%Add 0.08%2,573,969
SNYHOTCHKIS & WILEY 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 53.4910%Add 18.16%11,692,693
SNYNWQ Managers 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 53.4910%Add 22.12%2,941,923
SNYCharles Brandes 2014-12-31 Add0.21%$44.4 - $55
($48.49)
$ 53.4910%Add 14.36%2,571,795
SNYJames Barrow 2014-12-31 Add0.15%$44.4 - $55
($48.49)
$ 53.4910%Add 8.87%30,804,459
SNYDavid Dreman 2014-12-31 Buy $44.4 - $55
($48.41)
$ 53.4910%New holding1,102
SNYBill Nygren 2014-09-30 Add0.27%$50.89 - $57.29
($53.73)
$ 53.49-0%Add 14.55%5,670,000
SNYFirst Eagle Investment 2014-09-30 Reduce-0.07%$50.89 - $57.29
($53.73)
$ 53.49-0%Reduce 94.39%34,157
SNYNWQ Managers 2014-06-30 Reduce-1.31%$51.23 - $54.54
($53.08)
$ 53.491%Reduce 52.34%2,602,503
SNYBill Nygren 2014-06-30 Add0.9%$51.23 - $54.54
($53.08)
$ 53.491%Add 90.38%4,950,000
SNYBill Nygren 2014-03-31 Buy 1.1%$47.77 - $53.63
($50.68)
$ 53.496%New holding2,600,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-43.69view
Sanofi10% Owner 2015-01-26Buy647,448$95-43.69view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-42.59view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-20.02view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67597.39view

Press Releases about SNY :

Quarterly/Annual Reports about SNY:

    News about SNY:

    Articles On GuruFocus.com
    Ariel Capital Advisors bought Sanofi and Priceline in Q2 2015 Jul 31 2015 
    Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
    Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
    Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 
    Dodge & Cox Stock Fund First Quarter 2015 Commentary Apr 24 2015 
    Mt Stocks Apr 19 2015 
    Scottrade Mar 22 2015 
    Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
    Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
    FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 

    More From Other Websites
    Regeneron Pharmaceuticals Profit Doubles Aug 04 2015
    Sanofi's Insulin Toujeo® now Available for the Treatment of Adults with Diabetes in the UK Aug 04 2015
    Regeneron Still Has Legs: Leerink Targets $630 a Share Aug 03 2015
    Biogen, Inc. Earnings Analysis: By the Numbers Q2*, 2015 Aug 03 2015
    8:01 am Sanofi-Aventis announces that Vaccine published positive results, for cardio-respiratory... Aug 03 2015
    New Analysis Reports Lower Rates of Serious Cardio-Respiratory Events Among Study Participants... Aug 03 2015
    Sanofi Tops Q2 Earnings, Revenues Grow Y/Y, Maintains View - Analyst Blog Jul 31 2015
    Sanofi : Online Availability of Sanofi Group's Half-Year Financial Report for 2015 Jul 31 2015
    Sanofi (SNY) Earnings Report: Q2 2015 Conference Call Transcript Jul 30 2015
    Amgen beats big on bottom line Jul 30 2015
    Sales of MannKind's inhaled insulin continue slow start Jul 30 2015
    ​How many multiple sclerosis patients are in the U.S.? No one knows. Jul 30 2015
    10 Stocks Making Warren Buffett Richer in 2015 Jul 30 2015
    MannKind slumps after Sanofi details Afrezza sales Jul 30 2015
    MannKind slumps after Sanofi details Afrezza sales Jul 30 2015
    MannKind Afrezza Sales Underwhelming Again, Sanofi Reports Jul 30 2015
    ​Sanofi calls out Genzyme, multiple sclerosis drug, as main drivers of growth again Jul 30 2015
    A Health Care ETF Making new Highs Jul 30 2015
    Sanofi Delivers Solid Sales and Business EPS Growth in Q2 2015 Jul 30 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK